pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Structure Therapeutics Inc. ($GPCR) · news · pharmadog
← back to Structure Therapeutics Inc.
News mentioning $GPCR
10
stories
26d
Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12
endpoints
26d
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
biospace
Sep 3, 26
An AI drug specialist zeroes in on rare forms of obesity
biopharma dive
Sep 2, 26
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
biospace
Aug 28, 26
Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO
endpoints
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
Aug 19, 26
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
Aug 17, 26
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
Aug 17, 26
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
Jun 8, 26
#ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six months
endpoints
